9-ING-41
2102
Phase 2 small_molecule terminated
Quick answer
9-ING-41 for Salivary Gland Carcinoma is a Phase 2 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ACTUATE THERAPEUTICS, INC.
- Indication
- Salivary Gland Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated